PMID- 28005245
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20171209
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 161
IP  - 3
DP  - 2017 Feb
TI  - Aspirin/antiplatelet agent use improves disease-free survival and reduces the 
      risk of distant metastases in Stage II and III triple-negative breast cancer 
      patients.
PG  - 463-471
LID - 10.1007/s10549-016-4081-8 [doi]
AB  - PURPOSE: The objective is to define the therapeutic role of antiplatelet agents 
      in a triple-negative breast cancer (TNBC) population. METHODS: We performed 
      retrospective analysis using the UTSW TNBC registry containing data from 222 
      Stage II-III TNBC patients treated between 1998 and 2016. Univariate analysis and 
      multivariable logistic regression models were constructed to identify factors 
      associated with disease-free survival (DFS), distant metastases rate (DMR), and 
      overall survival outcomes. Antiplatelet drug use was determined by review of 
      electronic medical records. RESULTS: A total of 65 patients used antiplatelet 
      (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and 
      non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in 
      the AP group compared with the control group in 5-year DFS (80.4% at 5 years 
      compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 
      31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly 
      associated with improvements in DFS and DMR. CONCLUSIONS: We illustrate that 
      antiplatelet agent use improves DMR and DFS among a stage II and III TNBC 
      population despite our short follow-up evaluation. Longer follow-up evaluation 
      will be required to determine additional outcome advantage for antiplatelet agent 
      use. Our findings support consideration of investigation of antiplatelet therapy 
      as an adjunctive therapy for TNBC at high risk for disease recurrence.
FAU - Shiao, J
AU  - Shiao J
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Thomas, K M
AU  - Thomas KM
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Rahimi, A S
AU  - Rahimi AS
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Rao, R
AU  - Rao R
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Yan, Jingsheng
AU  - Yan J
AD  - Department of Clinical Sciences, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Xie, Xian-Jin
AU  - Xie XJ
AD  - Department of Clinical Sciences, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - DaSilva, M
AU  - DaSilva M
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Spangler, A
AU  - Spangler A
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Leitch, M
AU  - Leitch M
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Wooldridge, R
AU  - Wooldridge R
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Rivers, A
AU  - Rivers A
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Farr, D
AU  - Farr D
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Haley, B
AU  - Haley B
AD  - Department of Medical Oncology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Kim, D W Nathan
AU  - Kim DW
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA. 
      Nathan.kim@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
DEP - 20161222
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Treatment Outcome
MH  - Triple Negative Breast Neoplasms/diagnosis/*drug therapy/*mortality
OTO - NOTNLM
OT  - Anti-platelet
OT  - Aspirin
OT  - Estrogen receptor negative
OT  - Metastases
OT  - Triple negative
EDAT- 2016/12/23 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/12/23 06:00
PHST- 2016/10/13 00:00 [received]
PHST- 2016/12/08 00:00 [accepted]
PHST- 2016/12/23 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/12/23 06:00 [entrez]
AID - 10.1007/s10549-016-4081-8 [pii]
AID - 10.1007/s10549-016-4081-8 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2017 Feb;161(3):463-471. doi: 10.1007/s10549-016-4081-8. 
      Epub 2016 Dec 22.